1.Uribarri, J, del Castillo, MD, de la Maza, MP, et al. (2015) Dietary advanced glycation end products and their role in health and disease. Adv Nutr 15, 461–473.
2.Lin, JA, Wu, CH & Yen, GC (2018) Perspective of advanced glycation end products on human health. J Agric Food Chem 7, 2065–2070.
3.Vistoli, G, De Maddis, D, Cipak, A, et al. (2013) Advanced glycoxidation and lipoxidation end products (AGEs and ALEs): an overview of their mechanisms of formation. Free Radic Res 47 Suppl. 1, 3–27.
4.O’Brien, J & Morrissey, PA (1989) Nutritional and toxicological aspects of the Maillard browning reaction in foods. Crit Rev Food Sci Nutr 28, 211–248.
5.Goldberg, T, Cai, W, Peppa, M, et al. (2004) Advanced glycoxidation end products in commonly consumed foods. J Am Diet Assoc 104, 1287–1291.
6.Uribarri, J, Woodruff, S, Goodman, S, et al. (2010) Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 110, 911–916.
7.Koschinsky, T, He, C, Mitsuhashi, T, et al. (1997) Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci U S A 94, 6474–6479.
8.Uribarri, J, Cai, W, Ramdas, M, et al. (2011) Restriction of advanced glycation end products improves insulin resistance in human type 2 diabetes: potential role of AGER1 and SIRT1. Diabetes Care 34, 1610–1616.
9.Assar, SH, Moloney, C, Lima, M, et al. (2009) Determination of N ε-(carboxymethyl)lysine in food systems by ultra performance liquid chromatography–mass spectrometry. Amino Acids 36, 317–326.
10.Scheijen, JLJM, Clevers, E, Engelen, L, et al. (2016) Analysis of advanced glycation endproducts in selected food items by ultra-performance liquid chromatography tandem mass spectrometry: presentation of a dietary AGE database. Food Chem 190, 1145–1150.
11.Cerami, C, Founds, H, Nicholl, I, et al. (1997) Tobacco smoke is a source of toxic reactive glycation products. Proc Natl Acad Sci U S A 94, 13915–1320.
12.Sharma, C, Kaur, A, Thind, SS, et al. (2015) Advanced glycation end-products (AGEs): an emerging concern for processed food industries. J Food Sci Technol 52, 7561–7576.
13.Su, G, Li, L, Zhao, D, et al. (2018) The digestibility of hydrothermally-treated bovine serum albumin glycated by glyoxal. RSC Adv 8, 35870–35877.
14.Zhao, D, Li, L, Le, TT, et al. (2017) Digestibility of glyoxal-glycated β-casein and β-lactoglobulin and distribution of peptide-bound advanced glycation end products in gastrointestinal digests. J Agric Food Chem 19, 5778–5788.
15.Zhao, D, Le, TT, Larsen, LB, et al. (2017) Effect of glycation derived from α-dicarbonyl compounds on the in vitro digestibility of β-casein and β-lactoglobulin: a model study with glyoxal, methylglyoxal and butanedione. Food Res Int 102, 313–322.
16.Salazar-Villanea, S, Bruininx, EMAM, Gruppen, H, et al. (2016) Physical and chemical changes of rapeseed meal proteins during toasting and their effects on in vitro digestibility. J Anim Sci Biotechnol 7, 62.
17.Hellwig, M, Matthes, R, Peto, A, et al. (2014) N-ε-fructosyllysine and N-ε-carboxymethyllysine, but not lysinoalanine, are available for absorption after simulated gastrointestinal digestion. Amino Acids 46, 289–299.
18.Salazar-Villanea, S, Bruininx, EMAM, Gruppen, H, et al. (2017) Effects of toasting time on digestive hydrolysis of soluble and insoluble 00-rapeseed meal proteins. J Am Oil Chem Soc 94, 619–630.
19.Stefanie, G, Michael, H, Madlen, Z, et al. (2010) Transport of the advanced glycation end products alanylpyrraline and pyrralylalanine by the human proton-coupled peptide transporter hPEPT1. J Agric Food Chem 58, 2543–2547.
20.Hellwig, M, Geissler, S, Matthes, R, et al. (2011) Transport of free and peptide-bound glycated amino acids: synthesis, transepithelial flux at Caco-2 cell monolayers, and interaction with apical membrane transport proteins. Chembiochem 12, 1270–1279.
21.Förster, A, Kühne, Y & Henle, T (2005) Studies on absorption and elimination of dietary Maillard reaction products. Ann N Y Acad Sci 1043, 474–481.
22.Grunwald, S, Krause, R, Bruch, M, et al. (2006) Transepithelial flux of early and advanced glycation compounds across Caco-2 cell monolayers and their interaction with intestinal amino acid and peptide transport systems. Br J Nutr 95, 1221–1228.
23.Hellwig, M, Geissler, S, Peto, A, et al. (2009) Transport of free and peptide-bound pyrraline at intestinal and renal epithelial cells. J Agric Food Chem 57, 6474–6480.
24.Salazar-Villanea, S, Butré, CI, Wierenga, PA, et al. (2018) Apparent ileal digestibility of Maillard reaction products in growing pigs. PLOS ONE 5, e0199499.
25.DeChristopher, LR, Uribarri, J & Tucker, KL (2016) The link between soda intake and asthma; science points to high-fructose corn syrup, not the preservative: a commentary. Nutr Diabetes 6, e234.
26.Bains, Y, Gugliucci, A & Caccavello, R (2017) Advanced glycation endproducts form during ovalbumin digestion in the presence of fructose: inhibition by chlorogenic acid. Fitoterapia 120, 1–5.
27.Martinez-Saez, N, Fernandez-Gomez, B, Weijing, C, et al. (2019) In vitro formation of Maillard reaction products (MRPs) during simulated digestion of meal-resembling systems. Food Res Int 118, 72–80.
28.Aragno, M & Mastrocola, R (2017) Dietary sugars and endogenous formation of advanced glycation endproducts: emerging mechanisms of disease. Nutrients 9, E385.
29.Snelson, M & Coughlan, MT (2019) Dietary advanced glycation end products: digestion, metabolism and modulation of gut microbial ecology. Nutrients 11, E215.
30.Raman, KG, Sappington, PL, Yang, R, et al. (2006) The role of RAGE in the pathogenesis of intestinal barrier dysfunction after hemorrhagic shock. Am J Physiol Gastrointest Liver Physiol 291, G556–G565.
31.Vaziri, ND, Zhao, YY & Pahl, MV (2016) Altered intestinal microbial flora and impaired epithelial barrier structure and function in CKD: the nature, mechanisms, consequences and potential treatment. Nephrol Dial Transplant 31, 737–746.
32.Hellwig, M, Auerbach, C, Müller, N, et al. (2019) Metabolization of the advanced glycation end product N-ε-carboxymethyllysine (CML) by different probiotic E. coli strains. J Agric Food Chem 67, 1963–1972.
33.Seiquer, I, Rubio, LA, Peinado, MJ, et al. (2014) Maillard reaction products modulate gut microbiota composition in adolescents. Mol Nutr Food Res 58, 1552–1560.
34.Yacoub, R, Nugent, M, Cai, W, et al. (2017) Advanced glycation end products dietary restriction effects on bacterial gut microbiota in peritoneal dialysis patients; a randomized open label controlled trial. PLOS ONE 12, e0184789.
35.Yan, SF, Ramasamy, R & Schmidt, AM (2008) Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 4, 285–293.
36.Vlassara, H & Uribarri, J (2014) Advanced glycation end products (AGE) and diabetes: cause, effect, or both? Curr Diab Rep 14, 453.
37.Rojas, A, González, I & Añazco, C (2018) AGEs clearance mechanisms In Dietary AGEs and Their Roles in Health and Disease, pp. 37–49 [Uribarri, J, editor]. Boca Raton, FL: CRC Press.
38.Cai, W, He, JC, Zhu, L, et al. (2008) AGE-receptor-1 counteracts cellular oxidant stress induced by AGEs via negative regulation of p66shc-dependent FKHRL1 phosphorylation. Am J Physiol Cell Physiol 294, C145–C152.
39.Cai, W, He, JC, Zhu, L, et al. (2007) Reduced oxidant stress and extended lifespan in mice exposed to a low glycotoxin diet: association with increased AGER1 expression. Am J Pathol 170, 1893–1902.
40.Rojas, A, Delgado-López, F, González, I, et al. (2013) The receptor for advanced glycation end-products: a complex signaling scenario for a promiscuous receptor. Cell Signal 25, 609–614.
41.Hudson, BI & Lippman, ME (2018) Targeting RAGE signaling in inflammatory disease. Annu Rev Med 29, 349–364.
42.Hudson, BI, Kalea, AZ, Del Mar Arriero, M, et al. (2008) Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42. J Biol Chem 283, 34457–34446.
43.Ramasamy, R, Shekhtman, A & Schmidt, AM (2016) The multiple faces of RAGE – opportunities for therapeutic intervention in aging and chronic disease. Expert Opin Ther Targets 20, 431–446.
44.Ott, C, Jacobs, K, Haucke, E, et al. (2014) Role of advanced glycation end products in cellular signaling. Redox Biol 9, 411–429.
45.Hofmann, MA, Drury, S, Fu, C, et al. (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97, 889–901.
46.Wautier, MP, Guillausseau, PJ & Wautier, JL (2017) Activation of the receptor for advanced glycation end products and consequences on health. Diabetes Metab Syndr 11, 305–309.
47.Rojas, A, Figueroa, H & Morales, E (2010) Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis. Carcinogenesis 31, 334–341.
48.Reynaert, NL, Gopal, P, Rutten, EPA, et al. (2016) Advanced glycation end products and their receptor in age-related, non-communicable chronic inflammatory diseases; overview of clinical evidence and potential contributions to disease. Int J Biochem Cell Biol 81, 403–418.
49.Alleyn, M, Breitzig, M, Lockey, R, et al. (2019) Remission of fibrosis: rage to the rescue. J Cell Commun Signal 13, 119–120.
50.Bierhaus, A, Schiekofer, S, Schwaninger, M, et al. (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-κB. Diabetes 50, 2792–2808.
51.Kierdorf, K & Fritz, G (2013) RAGE regulation and signaling in inflammation and beyond. J Leukoc Biol 94, 55–68.
52.Sakaguchi, M, Murata, H, Aoyama, Y, et al. (2014) DNAX-activating protein 10 (DAP10) membrane adaptor associates with receptor for advanced glycation end products (RAGE) and modulates the RAGE-triggered signaling pathway in human keratinocytes. J Biol Chem 22, 23389–23402.
53.Sakaguchi, M, Murata, H, Yamamoto, K, et al. (2011) TIRAP, an adaptor protein for TLR2/4, transduces a signal from RAGE phosphorylated upon ligand binding. PLoS ONE 6, e23132.
54.Chen, YJ, Sheu, ML, Tsai, KS, et al. (2013) Advanced glycation end products induce peroxisome proliferator-activated receptor γ down-regulation-related inflammatory signals in human chondrocytes via Toll-like receptor-4 and receptor for advanced glycation end products. PLOS ONE 8, e66611.
55.Cheng, A, Dong, Y, Zhu, F, et al. (2013) AGE-LDL activates Toll like receptor 4 pathway and promotes inflammatory cytokines production in renal tubular epithelial cells. Int J Biol Sci 9, 94–107.
56.González, I, Romero, J, Rodríguez, BL, et al. (2013) The immunobiology of the receptor of advanced glycation end-products: trends and challenges. Immunobiology 218, 790–797.
57.Raucci, A, Cugusi, S, Antonelli, A, et al. (2008) A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J 22, 3716–3720.
58.Zhang, L, Bukulin, M, Kojro, E, et al. (2008) Receptor for advanced glycation end products is subjected to protein ectodomain shedding by metalloproteinases. J Biol Chem 283, 35507–35516.
59.Santilli, F, Vazzana, N, Bucciarelli, LG, et al. (2009) Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem 16, 940–952.
60.Yan, SD, Schmidt, AM, Anderson, GM, et al. (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269, 9889–9897.
61.Guo, J, Ananthakrishnan, R, Qu, W, et al. (2008) RAGE mediates podocyte injury in adriamycin-induced glomerulosclerosis. J Am Soc Nephrol 19, 961–972.
62.Wautier, JL, Wautier, MP, Schmidt, AM, et al. (1994) Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci U S A 91, 7742–7746.
63.Coughlan, MT, Thorburn, DR, Penfold, SA, et al. (2009) RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 20, 742–752.
64.Young, KG & Copeland, JW (2010) Formins and cell signaling. Biochim Biophys Acta 1803, 183–190.
65.Hordijk, PL (2006) Regulation of NADPH oxidases: the role of Rac proteins. Circ Res 98, 453–462.
66.Petry, A, Weitnauer, M & Görlach, A (2010) Receptor activation of NADPH oxidases. Antioxid Redox Signal 13, 467–487.
67.Acevedo, A & González-Billault, C (2018) Crosstalk between Rac1-mediated actin regulation and ROS production. Free Radic Biol Med 116, 101–113.
68.Elnakish, MT, Hassanain, HH, Janssen, PM, et al. (2013) Emerging role of oxidative stress in metabolic syndrome and cardiovascular diseases: important role of Rac/NADPH oxidase. J Pathol 231, 290–300.
69.Forrester, SJ, Kikuchi, DS, Hernandes, MS, et al. (2018) Reactive oxygen species in metabolic and inflammatory signaling. Circ Res 122, 877–902.
70.Li, Y & Pagano, PJ (2017) Microvascular NADPH oxidase in health and disease. Free Radic Biol Med 109, 33–47.
71.Liu, Z, Ren, Z, Zhang, J, et al. (2018) Role of ROS and nutritional antioxidants in human diseases. Front Physiol 9, 477.
72.Hoffmann, MH & Griffiths, HR (2018) The dual role of reactive oxygen species in autoimmune and inflammatory diseases: evidence from preclinical models. Free Radic Biol Med 125, 62–71.
73.Gloire, G, Legrand-Poels, S & Piette, J (2006) NF-κB activation by reactive oxygen species: fifteen years later. Biochem Pharmacol 72, 1493–1505.
74.Zhang, J, Wang, X, Vikash, V, et al. (2016) ROS and ROS-mediated cellular signaling. Oxid Med Cell Longev 2016, 4350965.
75.Blaser, H, Dostert, C, Mak, TW, et al. (2016) TNF and ROS crosstalk in inflammation. Trends Cell Biol 26, 249–261.
76.Buelna-Chontal, M & Zazueta, C (2013) Redox activation of Nrf2 & NF-κB: a double end sword? Cell Signal 25, 2548–2557.
77.Gloire, G & Piette, J (2009) Redox regulation of nuclear post-translational modifications during NF-κB activation. Antioxid Redox Signal 11, 2209–2222.
78.Cao, W, Hou, FF & Nie, J (2014) AOPPs and the progression of kidney disease. Kidney Int 4, 102–106.
79.Cristani, M, Speciale, A, Saija, A, et al. (2016) Circulating advanced oxidation protein products as oxidative stress biomarkers and progression mediators in pathological conditions related to inflammation and immune dysregulation. Curr Med Chem 23, 3862–3882.
80.Witko-Sarsat, V, Friedlander, M, Capeillere-Blandin, C, et al. (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 49, 1304–1313.
81.Witko-Sarsat, V, Friedlander, M, Nguyen Khoa, T, et al. (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161, 2524–2532.
82.Guo, ZJ, Niu, HX, Hou, FF, et al. (2008) Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal 10, 699–712.
83.Zhou, LL, Cao, W, Xie, C, et al. (2012) The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int 82, 759–770.
84.Yamamoto, Y & Yamamoto, H (2012) Interaction of receptor for advanced glycation end products with advanced oxidation protein products induces podocyte injury. Kidney Int 82, 733–735.
85.Zhou, LL, Cao, W, Xie, C, et al. (2012) The receptor of advanced glycation end products plays a central role in advanced oxidation protein products-induced podocyte apoptosis. Kidney Int 82, 759–770.
86.Wu, Q, Zhong, ZM, Zhu, SY, et al. (2016) Advanced oxidation protein products induce chondrocyte apoptosis via receptor for advanced glycation end products-mediated, redox-dependent intrinsic apoptosis pathway. Apoptosis 21, 36–50.
87.Anderson, MM, Requena, JR, Crowley, JR, et al. (1999) The myeloperoxidase system of human phagocytes generates N ε-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J Clin Invest 104, 103–113.
88.Anderson, MM & Heinecke, JW (2003) Production of N ε-(carboxymethyl)lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation. Diabetes 52, 2137–2143.
89.Schiekofer, S, Franke, S, Andrassy, M, et al. (2006) Postprandial mononuclear NF-κB activation is independent of the AGE-content of a single meal. Exp Clin Endocrinol Diabetes 114, 160–167.
90.Stirban, A, Negrean, M, Stratmann, B, et al. (2006) Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 29, 2064–2071.
91.Uribarri, J, Stirban, A, Sander, D, et al. (2007) Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 30, 2579–2582.
92.Negrean, M, Stirban, A, Stratmann, B, et al. (2007) Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 85, 1236–1243.
93.Davis, KE, Prasad, C, Vijayagopal, P, et al. (2015) Contribution of dietary advanced glycation end products (AGE) to circulating AGE: role of dietary fat. Br J Nutr 114, 1797–1806.
94.Vlassara, H, Cai, W, Goodman, S, et al. (2009) Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J Clin Endocrinol Metab 94, 4483–4491.
95.Birlouez-Aragon, I, Saavedra, G, Tessier, FJ, et al. (2010) A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases. Am J Clin Nutr 9, 1220–1226.
96.Semba, RD, Gebauer, SK, Baer, DJ, et al. (2014) Dietary intake of advanced glycation end products did not affect endothelial function and inflammation in healthy adults in a randomized controlled trial. J Nutr 144, 1037–1042.
97.Mark, AB, Poulsen, MW, Andersen, S, et al. (2014) Consumption of a diet low in advanced glycation end products for 4 weeks improves insulin sensitivity in overweight women. Diabetes Care 37, 88–95.
98.Macias-Cervantes, MH, Rodriguez-Soto, JMD, Uribarri, J, et al. (2015) Effect of a diet restricted in advanced glycation end products and exercise on metabolic parameters in adult overweight men. Nutrition 31, 446–451.
99.De Courten, B, de Courten, MP, Soldatos, G, et al. (2016) Diet low in advanced glycation end products increases insulin sensitivity in healthy overweight individuals: a double-blind, randomized, crossover trial. Am J Clin Nutr 103, 1426–1433.
100.Vlassara, H, Cai, W, Tripp, E, et al. (2016) Oral AGE restriction ameliorates insulin resistance in obese individuals with the metabolic syndrome: a randomised controlled trial. Diabetologia 59, 2181–2192.
101.Di Pino, A, Currenti, W, Urbano, F, et al. (2016) Low advanced glycation end product diet improves the lipid and inflammatory profiles of prediabetic subjects. J Clin Lipidol 10, 1098–1108.
102.Baye, E, de Courten, MP, Walker, K, et al. (2017) Effects of dietary advanced glycation end products on inflammation and cardiovascular risk in health overweight adults: a randomized crossover trial. Sci Rep 7, 4123.
103.Vlassara, H, Cai, W, Crandall, J, et al. (2002) Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci U S A 99, 15596–15601.
104.Luévano-Contreras, C, Garay-Sevilla, ME, Wrobel, K, et al. (2013) Dietary advanced glycation end products restriction diminishes inflammation markers and oxidative stress in patients with type 2 diabetes mellitus. J Clin Biochem Nutr 52, 22–26.
105.Uribarri, J, Peppa, M, Cai, W, et al. (2003) Restriction of dietary glycotoxins reduces excessive advanced glycation end products in renal failure patients. J Am Soc Nephrol 14, 728–731.
106.Yacoub, R, Nugent, M, Cai, W, et al. (2017) Advanced glycation end products dietary restriction effects on bacterial gut microbiota in peritoneal dialysis patients; a randomized open label controlled trial. PLOS ONE 12, e0184789.
107.Kellow, NJ & Coughlan, MT (2015) Effects of diet derived advanced glycation end products on inflammation. Nutr Rev 73, 737–759.
108.Cai, W, Ramdas, M, Zhu, L, Chen, X, et al. (2012) Oral advanced glycation endproducts (AGEs) promote insulin resistance and diabetes by depleting the antioxidant defenses AGE receptor-1 and sirtuin 1. Proc Natl Acad Sci U S A 109, 15888–15893.
109.Iwashige, K, Kouda, K, Kouda, M, et al. (2004) Calorie restricted diet and urine pentosidine in patients with rheumatoid arthritis. J Physiol Anthropol Appl Human Sci 23, 19–24.
110.Gugliucci, A, Kotani, K, Taing, J, et al. (2009) Short-term calorie diet intervention reduces serum advanced glycation end products in healthy overweight or obese adults. Ann Nutr Metab 54, 197–201.
111.Rodriguez, JM, Leiva Balich, L, Concha, MJ, et al. (2015) Reduction of serum advanced glycation end products with a low calorie Mediterranean diet. Nutr Hosp 31, 2511–2517.
112.Lopez-Moreno, J, Quintana-Navarro, GM, Delgado-Lista, J, et al. (2016) Mediterranean diet reduces serum advanced glycation end products and increases antioxidant defenses in elderly adults: a randomized controlled trial. J Am Geriatr Soc 64, 901–904.
114.Vlassara, H, Torreggiani, M, Post, JB, et al. (2009) Role of oxidants/inflammation in declining renal function in chronic kidney disease and normal aging. Kidney Int 114, S3–S11.
115.Henning, RJ (2018) Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol 14, 491–509.
116.Turner, RC, Millns, H, Neil, HAW, et al. (1998) Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 316, 823–828.
117.Stirban, A, Negrean, M, Götting, C, et al. (2008) Dietary advanced glycation endproducts and oxidative stress: in vivo effects on endothelial function and adipokines. Ann N Y Acad Sci 1126, 276–279.
118.Baye, E, Kiriakova, V, Uribarri, J, et al. (2017) Consumption of diets with low advanced glycation end products improves cardiometabolic parameters: meta-analysis of randomised controlled trials. Sci Rep 7, 43–51.
119.West, RK, Moshier, E, Lubitz, I, et al. (2014) Dietary advanced glycation end products are associated with decline in memory in young elderly. Mech Ageing Dev 140, 10–12.
120.Ahmed, N, Ahmed, U, Thornalley, PJ, et al. (2005) Protein glycation, oxidation and nitration adduct residues and free adducts of cerebrospinal fluid in Alzheimer’s disease and link to cognitive impairment. J Neurochem. 92, 255–263.
121.Bär, KJ, Franke, S, Wenda, B, et al. (2003) Pentosidine and N ε-(carboxymethyl)-lysine in Alzheimer’s disease and vascular dementia. Neurobiol Aging 24, 333–338.
122.Meli, M, Perier, C, Ferron, C, et al. (2002) Serum pentosidine as an indicator of Alzheimer’s disease. J.Alzheimers. Dis 4, 93–96.
123.Cai, W, Uribarri, J, Zhu, L, et al. (2014) Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. Proc Natl Acad Sci U S A 111, 4940–4945.
124.Thome, J, Munch, G, Muller, R, et al. (1996) Advanced glycation endproducts-associated parameters in the peripheral blood of patients with Alzheimer’s disease. Life Sci 59, 679–685.
125.Yaffe, K, Lindquist, K, Schwartz, AV, et al. (2011) Advanced glycation end product level, diabetes, and accelerated cognitive aging. Neurology 77, 1351–1356.
126.Luth, HJ, Ogunlade, V, Kuhla, B, et al. (2005) Age- and stage-dependent accumulation of advanced glycation end products in intracellular deposits in normal and Alzheimer’s disease brains. Cereb Cortex 15, 211–220.
127.Takeda, A, Wakai, M, Niwa, H, et al. (2001) Neuronal and glial advanced glycation end product [N ε-(carboxymethyl)lysine] in Alzheimer’s disease brains. Acta Neuropathol 10, 27–35.
128.Girones, X, Guimera, A, Cruz-Sanchez, CZ, et al. (2004) N ε-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer’s disease. Free Radic Biol Med 36, 1241–1247.
129.Yan, SD, Chen, X, Schmidt, AM, et al. (1994) Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci U S A 91, 7787–7791.
130.Yan, SD, Chen, X, Fu, J, et al. (1996) RAGE and amyloid-β peptide neurotoxicity in Alzheimer’s disease. Nature 382, 685–691.
131.Vitek, MP, Bhattacharya, K, Glendening, JM, et al. (1994) Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A 91, 4766–4770.
132.Sasaki, N, Fukatsu, R, Tsuzuki, K, et al. (1998) Advanced glycation end products in Alzheimer’s disease and other neurodegenerative diseases. Am J Pathol 153, 1149–1155.
133.Arvanitakis, Z, Tounsi, H, Pillon, B, et al. (1999) Fronto-temporal dementia: a clinical approach. Rev Neurol (Paris) 155, 113–119.
134.Moran, C, Munch, G, Forbes, JM, et al. (2015) Type 2 diabetes, skin autofluorescence, and brain atrophy. Diabetes 64, 279–283.
135.Hudson, BI, Moon, YP, Kalea, AZ, et al. (2011) Association of serum soluble receptor for advanced glycation end-products with subclinical cerebrovascular disease: the Northern Manhattan Study (NOMAS). Atherosclerosis 216, 192–198.
136.Miki, S, Kasayama, S, Miki, Y, et al. (1993) Expression of receptors for advanced glycosylation end products on renal cell carcinoma cells in vitro. Biochem Biophys Res Commun 196, 984–989.
137.Abe, R & Yamagishi, S (2008) AGE–RAGE system and carcinogenesis. Curr Pharm Des 14, 940–945.
138.Riehl, A, Nemeth, J, Angel, P, et al. (2009) The receptor RAGE: bridging inflammation and cancer. Cell Commun Signal 7, 12.
139.Rojas, A, Añazco, C, González, I, et al. (2018) Extracellular matrix glycation and receptor for advanced glycation end-products activation: a missing piece in the puzzle of the association between diabetes and cancer. Carcinogenesis 39, 515–521.
140.Palanissami, G & Paul, SFD (2018) RAGE and its ligands: molecular interplay between glycation, inflammation, and hallmarks of cancer – a review. Horm Cancer 9, 295–325.
141.Ahmad, S, Khan, MY, Rafi, Z, et al. (2018) Oxidation, glycation and glycoxidation – the vicious cycle and lung cancer. Semin Cancer Biol 49, 29–33.
142.Turner, DP (2017) The role of advanced glycation end-products in cancer disparity. Adv Cancer Res 133, 1–22.
143.Walter, KR, Ford, ME, Gregoski, MJ, et al. (2019) Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention. Breast Cancer Res Treat 173, 559–571.
144.Cruz-Jentoft, AJ, Bahat, G, Bauer, J, et al. (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Aging 48, 16–31.
145.Rosenberg, IH & Roubenoff, R (1995) Stalking sarcopenia. Ann Intern Med 123, 727–728.
146.Dalal, M, Ferrucci, L.Sun, K, et al. (2009) Elevated serum advanced glycation end products and poor grip strength in older community-dwelling women. Gerontol A Biol Sci Med Sci 64, 132–137.
147.Kato, M, Kubo, A, Sugioka, Y, et al. (2017) Relationship between advanced glycation end-product accumulation and low skeletal muscle mass in Japanese men and women. Geriatr Gerontol Int 17, 785–790.
148.Mori, H, Kuroda, A, Araki, M, et al. (2017) Advanced glycation end-products are a risk for muscle weakness in Japanese patients with type 1 diabetes. J Diabetes Investig 8, 377–382.
149.Haus, JM, Carrithers, JA, Trappe, SW, et al. (2007) Collagen, cross-linking, and advanced glycation end products in aging human skeletal muscle. J Appl Physiol 103, 2068–2076.
150.Eguchi, Y, Toyoguchi, T, Inage, K, et al. (2018) Pentosidineconcentration is associated with degenerative lumbar scoliosis in older women: preliminary results. Eur Spine J 27, 597–606.
151.Drenth, H, Zuidema, S, Bunt, S, et al. (2016) The contribution of advanced glycation end product (AGE) accumulation to the decline in motor function. Eur Rev Aging Phys Act 13, 3.